FDA Chief Faces CBD Questions At Congressional Hearing

FDA Chief Faces CBD Questions At Congressional Hearing

The head of the Food and Drug Administration (FDA) explained the agency’s progress in establishing regulations for CBD in response to questioning from a pair of bipartisan lawmakers at a congressional hearing on Wednesday. FDA Commissioner Stephen Hahn discussed enforcement actions the agency has taken against companies that have made unsanctioned claims about the medical benefits of their cannabidiol products and said additional research is needed before decisions are made about further enforcement guidance or allowing such products to be lawfully marketed. “We have a knowledge gap, sir, that makes it difficult for us to know how to proceed in several areas,” Hahn said in response to a question from Rep. Andy Harris (R-MD) during the House Appropriations subcommittee hearing on FDA’s Fiscal Year 2021 budget request. The commissioner noted that FDA has issued warnings to businesses claiming their CBD products can treat cancer or Alzheimer’s disease, which he described as “the highest risk areas.” “We will continue to enforce that,” he said. “We are exploring the possibility of some regulatory approaches from an enforcement approach that should help us actually get to the right place and prioritize the highest risk areas.” Watch the exchange below:    Later, Rep. Chellie Pingree (D-ME) pressed Hahn on the lack of clarity for consumers and CBD manufacturers, and he replied that he appreciated the concern but stressed there’s a need for a “balanced and pragmatic approach here.” “These products are out there and we have to acknowledge that,” he said. “The American people…

Excerpt only …
READ MORE BELOW
Source : MJ moment
Link to original : FDA Chief Faces CBD Questions At Congressional Hearing
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.